

1 **Genome-wide association study of placental weight in 179,025 children and** 2 **parents reveals distinct and shared genetic influences between placental and fetal** 3 **growth** 4

5 Robin N. Beaumont^{1*}, Christopher Flatley^{2,3*}, Marc Vaudel^{4*}, Xiaoping Wu⁵, Jing Chen⁶, Gunn-
6 Helen Moen^{7,8,9,10,11}, Line Skotte⁵, Øyvind Helgeland^{4,3}, Pol Sole-Navais², Karina Banasik¹², Clara
7 Albiñana¹³, Justiina Ronkainen¹⁴, João Fadista^{5,15,16}, Sara Elizabeth Stinson¹⁷, Katerina
8 Trajanoska^{18,19}, Carol A Wang^{20,21}, David Westergaard^{12,22,23}, Sundararajan Srinivasan²⁴, Carlos
9 Sánchez-Soriano²⁵, Jose Ramon Bilbao^{26,27,28}, Catherine Allard²⁹, Marika Groleau³⁰, Teemu
10 Kuulasmaa³¹, Daniel J. Leirer¹, Frédérique White³⁰, Pierre-Étienne Jacques^{30,29}, Haoxiang Cheng³²,
11 Ke Hao³², Ole A. Andreassen^{33,34}, Bjørn Olav Åsvold^{35,36,37}, Mustafa Atalay³¹, Laxmi Bhatta³⁵, Luigi
12 Bouchard^{38,39}, Ben Michael Brumpton^{35,36,40}, Søren Brunak¹², Jonas Bybjerg-Grauholm^{41,42}, Cathrine
13 Ebbing^{43,44}, Paul Elliott⁴⁵, Line Engelbrechtsen^{46,17}, Christian Erikstrup^{47,48}, Marisa Estarlich^{49,50,51},
14 Steve Franks⁵², Romy Gaillard^{53,54}, Frank Geller⁵, Jakob Grove^{55,42,56,57}, David M Hougaard^{41,42}, Eero
15 Kajantie^{58,59}, Camilla S. Morgen^{17,60}, Ellen A Nohr⁶¹, Mette Nyegaard⁶², Colin NA Palmer²⁴, Ole
16 Birger Pedersen^{63,64}, The Early Growth Genetics (EGG) Consortium⁶⁵, Fernando Rivadeneira^{18,53},
17 Sylvain Sebert¹⁴, Beverley M. Shields¹, Camilla Stoltenberg^{69,70}, Ida Surakka⁷¹, Lise Wegner
18 Thørner⁷², Henrik Ullum⁷³, Marja Vaarasmaki^{74,75}, Bjarni J Vilhjalmsson^{13,57}, Cristen J. Willer^{71,76,77},
19 Timo A. Lakka^{31,78,79}, Dorte Jensen Gybel-Brask⁸⁰, Mariona Bustamante^{81,82,83}, Torben Hansen¹⁷,
20 Ewan R Pearson²⁴, Rebecca Reynolds²⁵, Sisse R. Ostrowski^{72,84}, Craig E Pennell^{20,21}, Vincent W. V.
21 Jaddoe^{53,54}, Janine F Felix^{53,54}, Andrew T. Hattersley¹, Mads Melbye^{85,86,87,88}, Deborah A. Lawlor^{89,90},
22 Kristian Hveem^{35,36}, Thomas Werge^{91,85,92,42}, Henriette Svarre Nielsen^{22,84}, Per Magnus⁹³, David M
23 Evans^{11,8,89}, Bo Jacobsson^{2,3}, Marjo-Riitta Jarvelin^{14,45,94,95}, Ge Zhang^{96,97}, Marie-France Hivert^{98,99},
24 Stefan Johansson^{4,100**}, Rachel M. Freathy^{1,89**}, Bjarke Feenstra^{5,72**}, Pål R. Njølstad^{4,101**}

25
26 ¹Department of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of
27 Exeter, Exeter, UK, ²Department of Obstetrics and Gynecology, Institute of Clinical Sciences,
28 Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ³Department of Genetics
29 and Bioinformatics, Health Data and Digitalization, Norwegian Institute of Public Health, Oslo,
30 Norway, ⁴Center for Diabetes Research, Department of Clinical Science, University of Bergen,
31 Bergen, Norway, ⁵Department of Epidemiology Research, Statens Serum Institut, Copenhagen,
32 Denmark, ⁶Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center,
33 Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, United
34 States of America, ⁷Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway.,
35 ⁸University of Queensland Diamantina Institute, The University of Queensland, Brisbane, Australia,
36 ⁹K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, NTNU,
37 Norwegian University of Science and Technology, Norway, ¹⁰Population Health Science, Bristol
38 Medical School, University of Bristol, UK., ¹¹Institute for Molecular Bioscience, The University of
39 Queensland, Brisbane, Australia, ¹²Translational Disease Systems Biology, Novo Nordisk
40 Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Denmark,
41 ¹³National Centre for Register-Based Research, Aarhus University, Aarhus, Denmark, ¹⁴Research
42 Unit of Population Health, University of Oulu, Oulu, Finland, ¹⁵Department of Clinical Sciences,
43 Lund University Diabetes Centre, Malmö, Sweden, ¹⁶Institute for Molecular Medicine Finland

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

44 (FIMM), University of Helsinki, Helsinki, Finland, ¹⁷Novo Nordisk Foundation Center for Basic
45 Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen,
46 Copenhagen, Denmark, ¹⁸Department of Internal Medicine, Erasmus MC, University Medical
47 Center Rotterdam, Rotterdam, The Netherlands, ¹⁹Department of Human Genetics, McGill
48 University, Montréal, Québec, Canada., ²⁰School of Medicine and Public Health, College of
49 Medicine, Public Health and Wellbeing, The University of Newcastle, Newcastle, New South Wales,
50 Australia, 2308, ²¹Hunter Medical Research Institute, New Lambton Heights, New South Wales,
51 Australia, ²²Dept. of Obstetrics and Gynecology, Copenhagen University Hospital, Hvidovre,
52 Denmark, ²³Methods and Analysis, Statistics Denmark. Copenhagen, Denmark, ²⁴Division of
53 Population Health & Genomics, School of Medicine, University of Dundee, Dundee, ²⁵Centre for
54 Cardiovascular Science, The University of Edinburgh, Edinburgh, United Kingdom, ²⁶Dpt. of
55 Genetics, Physical Anthropology and Animal Physiology, University of the Basque Country
56 (UPV/EHU) Leioa, Spain, ²⁷Biocruces-Bizkaia Health Research Institute, Barakaldo, Spain, ²⁸Spanish
57 Biomedical Research Center in Diabetes and Associated Metabolic Disorders (CIBERDEM), Spain,
58 ²⁹Centre de recherche du Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, QC,
59 ³⁰Département de Biologie, Faculté des Sciences, Université de Sherbrooke, Sherbrooke, Québec,
60 Canada, ³¹Institute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio
61 Campus, Finland, ³²Icahn School of Medicine at Mount Sinai, ³³NORMENT Centre, Institute of
62 Clinical Medicine, University of Oslo, Oslo, Norway, ³⁴Division of Mental Health and Addiction, Oslo
63 University Hospital, NO-0315 Oslo, Norway, ³⁵K.G. Jebsen Center for Genetic Epidemiology,
64 Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology,
65 Trondheim, Norway, ³⁶HUNT Research Centre, Department of Public Health and Nursing, NTNU,
66 Norwegian University of Science and Technology, Levanger, Norway, ³⁷Department of
67 Endocrinology, Clinic of Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim,
68 Norway., ³⁸Department of Biochemistry and Functional Genomics, Faculty of Medicine and Health
69 Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada., ³⁹Clinical Department of
70 Laboratory Medicine, Centre intégré universitaire de santé et de services sociaux (CIUSSS) du
71 Saguenay–Lac-St-Jean – Hôpital Universitaire de Chicoutimi, Saguenay, Québec, Canada., ⁴⁰Clinic
72 of Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, ⁴¹Department
73 for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark, ⁴²iPSYCH, The Lundbeck
74 Foundation Initiative for Integrative Psychiatric Research, Aarhus, Denmark, ⁴³Department of
75 Clinical Science, University of Bergen, Bergen, Norway, ⁴⁴Department of Gynecology and
76 Obstetrics, Haukeland University Hospital, Bergen, Norway, ⁴⁵Department of Epidemiology and
77 Biostatistics, School of Public Health, Imperial College London, London, United Kingdom,
78 ⁴⁶Department of Obstetrics and Gynecology, Hillerød Hospital, Denmark, ⁴⁷Dept. Clinical
79 Immunology, Aarhus University Hospital, Aarhus, Denmark, ⁴⁸Dept. Clinical Medicine, Aarhus
80 University, Aarhus, Denmark, ⁴⁹Faculty of nursing and chiropody, Universitat de València,
81 C/Menendez Pelayo, Valencia, Spain, ⁵⁰Epidemiology and Environmental Health Joint Research
82 Unit, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region,
83 FISABIO-Public Health, FISABIO-Universitat Jaume I-Universitat de València, Av. Catalunya 21,
84 Valencia, Spain, ⁵¹Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP),
85 Madrid, Spain, ⁵²Institute of Reproductive and Developmental Biology, Imperial College London,
86 United Kingdom, ⁵³The Generation R Study Group, Erasmus MC, University Medical Center
87 Rotterdam, Rotterdam, The Netherlands, ⁵⁴Department of Pediatrics, Erasmus MC, University
88 Medical Center Rotterdam, Rotterdam, The Netherlands, ⁵⁵Department of Biomedicine - Human

89 Genetics and the iSEQ Center, Aarhus University, Aarhus, Denmark, ⁵⁶Center for Genomics and
90 Personalized Medicine, Aarhus, Denmark, ⁵⁷Bioinformatics Research Centre, Aarhus University,
91 Aarhus, Denmark, ⁵⁸PEDEGO Research Unit, Medical Research Center, University of Oulu and Oulu
92 University Hospital, Oulu, Finland, ⁵⁹Population Health Unit, Finnish Institute for Health and
93 Welfare, Helsinki and Oulu, Finland, ⁶⁰National Institute of Public Health, University of Southern
94 Denmark, Copenhagen, Denmark, ⁶¹Institute of Clinical research, University of Southern Denmark,
95 Odense, Denmark, ⁶²Department of Health Science and Technology, Aalborg University, Denmark,
96 ⁶³Dept. of Clinical Immunology, Zealand University Hospital, Køge, Denmark, ⁶⁴Dept. of Clinical
97 Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen,
98 Denmark, ⁶⁵A list of members and affiliations appears in the Supplementary Note, ⁶⁶Department
99 for Genomics of Common Diseases, School of Medicine, Imperial College London, London United
100 Kingdom, ⁶⁷Department of Clinical and Molecular Medicine, Norwegian University of Science and
101 Technology, Trondheim, Norway, ⁶⁸Pediatric Research Centre, Helsinki University Hospital and
102 University of Helsinki, Helsinki, Finland, ⁶⁹Norwegian Institute of Public Health, Oslo, Norway,
103 ⁷⁰Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway,
104 ⁷¹Department of Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI
105 48109, USA, ⁷²Dept. of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet,
106 Copenhagen, Denmark, ⁷³Statens Serum Institut, Copenhagen, Denmark, ⁷⁴PEDEGO Research Unit,
107 Medical Research Center, University of Oulu, Oulu, Finland, ⁷⁵Department of Obstetrics and
108 Gynaecology, Oulu University Hospital, Oulu, Finland, ⁷⁶Department of Biostatistics and Center for
109 Statistical Genetics, University of Michigan, Ann Arbor, MI, USA, ⁷⁷Department of Human Genetics,
110 University of Michigan, Ann Arbor, MI, USA, ⁷⁸Department of Clinical Physiology and Nuclear
111 Medicine, Kuopio University Hospital, Kuopio, Finland, ⁷⁹Foundation for Research in Health
112 Exercise and Nutrition, Kuopio Research Institute of Exercise Medicine, Kuopio, Finland,
113 ⁸⁰Psychotherapeutic Outpatient Clinic, Mental Health Services, Capital Region, Copenhagen
114 Denmark, ⁸¹ISGlobal, Institute for Global Health, Barcelona, Spain, ⁸²Universitat Pompeu Fabra
115 (UPF), Barcelona, Spain, ⁸³Spanish Consortium for Research on Epidemiology and Public Health
116 (CIBERESP), Madrid, Spain, ⁸⁴Dept. of Clinical Medicine, University of Copenhagen, Copenhagen,
117 Denmark, ⁸⁵Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark,
118 ⁸⁶K.G. Jebsen Center for Genetic Epidemiology, Norwegian University of Science and Technology,
119 Trondheim, Norway, ⁸⁷Norwegian Institute of Public Health, Oslo, Norway, ⁸⁸Department of
120 Genetics, Stanford University School of Medicine, Stanford, California, USA, ⁸⁹Medical Research
121 Council Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom, ⁹⁰Population
122 Health Science, Bristol Medical School, University of Bristol, Bristol, UK, ⁹¹Institute of Biological
123 Psychiatry, Mental Health Services, Copenhagen University Hospital, Copenhagen, Denmark,
124 ⁹²Lundbeck Center for Geogenetics, GLOBE Institute, University of Copenhagen, Copenhagen,
125 Denmark, ⁹³Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway.,
126 ⁹⁴MRC Centre for Environment and Health, School of Public Health, Imperial College London,
127 London, ⁹⁵Unit of Primary Health Care, Oulu University Hospital, OYS, Oulu, Finland, ⁹⁶Division of
128 Human Genetics, Cincinnati Children's Hospital Medical Center, Department of Pediatrics,
129 University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America, ⁹⁷Center
130 for Prevention of Preterm Birth, Perinatal Institute, Cincinnati Children's Hospital Medical Center
131 and March of Dimes Prematurity Research Center Ohio Collaborative, Cincinnati Children's
132 Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine,
133 Cincinnati, Ohio, United States of America, ⁹⁸Department of Population Medicine, Harvard Medical

134 School, Harvard Pilgrim Health Care Institute, Boston, MA, ⁹⁹Diabetes Unit, Massachusetts General
135 Hospital, MA, Boston, ¹⁰⁰Department of Medical Genetics, Haukeland University Hospital, Bergen,
136 Norway, ¹⁰¹Children and Youth Clinic, Haukeland University Hospital, Bergen, Norway

137

138

139

140 *These authors contributed equally to this work

141 **These authors jointly directed this work

142

143

144

145 Abstract

146 A well-functioning placenta is essential for fetal and maternal health throughout pregnancy. Using placental
147 weight after term delivery as a proxy for placental growth, we report genome-wide association analyses in
148 the fetal ($n = 65,405$), maternal ($n = 61,228$), and paternal ($n = 52,392$) genomes, yielding 40 independent
149 association signals. Twenty-six signals are confidently classified as fetal only, four maternal only, and three
150 fetal and maternal. A maternal parent-of-origin effect is seen near *KCNQ1*. Genetic correlation and
151 colocalization analyses reveal overlap with birth weight genetics, but twelve loci are classified as
152 predominantly or only affecting placental weight, with connections to placental development and
153 morphology, and transport of antibodies and amino acids. Mendelian randomization analyses indicate that
154 fetal genetically mediated higher placental weight is causally associated with risk of preeclampsia or shorter
155 gestational duration. Moreover, these analyses support a role for insulin produced by the fetus in
156 regulating the growth of the placenta, providing a key link between fetal and placental growth.

157

158

159 Main

160 The placenta is a remarkable pregnancy organ formed after implantation of the blastocyst into the uterine
161 wall. The intimate placental connection between mother and fetus provides nutrients and oxygen to the
162 developing fetus, while removing waste products from the fetal blood. The placenta produces hormones,
163 growth factors, and cytokines, and allows maternal IgG antibodies to be passed to the fetus, giving
164 newborns innate immunity. Suboptimal placentation can lead to intrauterine growth restriction¹,
165 spontaneous abortion, preterm birth², and preeclampsia^{3,4}, and a poorly functioning placenta is associated
166 with higher risk of growth restriction⁵, adverse neurodevelopment⁶, and cardiometabolic diseases⁷⁻¹¹.

167 Placental weight (PW) is an easily available measure often used in epidemiological studies^{12,13} as a proxy for
168 placental growth and function. The close relationship between placental and fetal growth is reflected by a
169 positive correlation ($r = 0.6$) between PW and birth weight (BW) in large cohorts^{12,14}. Several genome-wide
170 association studies (GWAS) have identified genetic loci in the maternal and fetal genomes associated with
171 BW^{15,16}, and BW-associated loci are enriched for placental expression quantitative trait loci (eQTLs)¹⁷.
172 However, no GWAS of PW is available to date, and it remains unclear how the genetics of placental growth
173 relate to the genetics of fetal growth or to the genetics of adverse pregnancy outcomes such as
174 preeclampsia. While the placenta is primarily composed of cells with fetal origin, it is intricately connected
175 to maternal tissues and circulation^{18,19}. Genetic analyses offer the opportunity for insight into the complex
176 interplay of direct fetal, indirect maternal, and parent-of-origin effects (POE), which we hypothesize
177 underlie placental growth and function.

178 We conducted the first GWAS of PW in term, singleton pregnancies, meta-analyzing data from 28 European
179 studies. Analyses of 19,861 child-mother-father trios with PW measurements enabled a better
180 understanding of the relationship between fetal and maternal effects, including POE. We also categorized
181 loci according to their association with BW, examined genetic links between PW and pregnancy, perinatal
182 and later-life outcomes, and used Mendelian randomization (MR) to assess causal relationships between
183 maternal and offspring characteristics and PW.

184

185 Results


186 Meta-analyses of fetal, maternal, and paternal GWASs

187 We performed GWAS meta-analyses of PW adjusted for fetal sex and gestational duration against the fetal
188 ($n = 65,405$), maternal ($n = 61,228$), and paternal genomes ($n = 52,392$) (Fig. 1.). Methods and
189 Supplementary Tables 1-6 provide information on data collection and genotyping. After data cleaning and
190 imputation, 11 million SNPs were analyzed. The fetal GWAS meta-analysis identified 32 independent loci at
191 $P < 5 \times 10^{-8}$, the maternal analysis identified four loci, and the paternal identified two loci (Fig. 2, Table 1,
192 Supplementary Table 7). Approximate conditional and joint analysis (COJO) further identified secondary
193 association signals at three fetal loci (Methods; Table 1; Supplementary Table 7). A comparison of effect
194 sizes against minor allele frequencies for those 41 association signals was in line with expectations from
195 statistical power (Supplementary Fig. 1). We also conducted analyses adjusted only for sex (*i.e.* not
196 gestational age), which showed high genetic correlations with our main analysis results (fetal $r_g = 1.00$,
197 $SE = 0.001$, $P \leq 1 \times 10^{-16}$; maternal $r_g = 0.99$, $SE = 0.001$, $P \leq 1 \times 10^{-16}$; paternal $r_g = 1.00$, $SE = 0.004$,
198 $P \leq 1 \times 10^{-16}$). Four additional loci reached genome-wide significance in the fetal sex-adjusted analyses, all
199 of which were close to genome-wide significance in our main fetal analysis (Supplementary Table 8).
200 Regional association plots for all genome-wide significant loci in the main analyses are shown in
201 Supplementary Fig. 2a-e.

202

203

204 **Fig. 1: Flow chart of the study design.**
205




206
207
208
209
210
211
212
213

Abbreviations: eQTL, expression quantitative trait loci; GWAS, genome-wide association study; HRC, Haplotype Reference Consortium; MAC, minor allele content; meQTL: methylation quantitative trait loci; PC, principal component.

214 **Fig. 2: Genome-wide association results for PW.**

215



216

217

218 Manhattan plots of $-\log_{10} P$ values across the chromosomes and corresponding quantile–quantile plot of
219 observed versus expected $-\log_{10} P$ values for meta-analyses of SNP associations with placental weight in **a**,
220 the fetal GWAS; **b**, the maternal GWAS; and **c**, the paternal GWAS.

221

222

223

224
225

Table 1: Variants associated with PW (adjusted for sex and gestational duration) in the fetal, maternal, and paternal GWAS meta-analyses.

Locus Name	Chr	Position (b37)	rsid	EA	OA	Effect Allele Frequency	Beta	SE	P	N	Maternal Fetal Classification	PW/BW Classification
Fetal												
<i>DCST2</i>	1	155001281	rs150138294	A	G	0.053	0.080	0.013	1.07E-09	65405	Unclassified	PW & BW same direction
<i>RPL31P11</i>	1	161651064	rs723177	T	C	0.296	0.039	0.006	1.02E-10	65405	Fetal	Predominantly or only PW
<i>TSNAX-DISC1, LINC00582</i>	1	231733795	rs1655296	G	T	0.393	0.042	0.006	4.86E-14	65405	Fetal	Predominantly or only PW
<i>TSNAX-DISC1, LINC00582*</i>	1	231794081	rs140691414	T	C	0.007	0.261	0.039	2.54E-11	57158	Fetal	PW & BW same direction
<i>CHRM3</i>	1	239822859	rs10925945	T	C	0.936	0.067	0.011	1.69E-09	65405	Unclassified	Predominantly or only PW
<i>EPAS1</i>	2	46567276	rs4953353	G	T	0.622	0.042	0.007	1.38E-10	48809	Unclassified	PW & BW same direction
<i>ADCY5</i>	3	123065778	rs11708067	G	A	0.233	0.053	0.007	1.83E-16	65405	Fetal & Maternal	PW & BW same direction
<i>LOC339894/CCNL1</i>	3	156795414	rs9817452	G	T	0.614	0.040	0.006	1.72E-12	65405	Fetal	PW & BW same direction
<i>PDLIM5</i>	4	95531563	rs74457440	A	G	0.233	0.036	0.007	3.37E-08	65405	Unclassified	PW & BW same direction
<i>ACTBL2</i>	5	57073666	rs7722058	T	C	0.845	0.047	0.008	6.06E-10	65405	Fetal	PW & BW same direction
<i>HSPA4</i>	5	132444128	rs72801474	A	G	0.105	0.055	0.009	7.34E-09	65405	Fetal	Predominantly or only PW
<i>ARHGAP26</i>	5	142429811	rs3822394	C	A	0.263	0.036	0.006	5.80E-09	65405	Fetal	Predominantly or only PW
<i>EBF1</i>	5	158433339	rs67265526	T	C	0.628	0.032	0.006	1.12E-08	65405	Fetal	Predominantly or only PW
<i>NUDT3</i>	6	34237188	rs541641049	A	G	0.018	0.193	0.035	4.52E-08	55263	Fetal	PW & BW same direction
<i>FKBP5/MAPK13/TEAD3</i>	6	35517390	rs9800506	T	G	0.410	0.033	0.006	2.58E-09	65405	Unclassified	PW & BW same direction
<i>HACE1</i>	6	105130521	rs12529634	C	T	0.872	0.056	0.008	2.85E-11	65405	Fetal	PW & BW same direction
<i>ESR1</i>	6	152042413	rs11756568	A	T	0.703	0.052	0.006	1.95E-18	65405	Fetal	PW & BW same direction
<i>PDE10A</i>	6	166182483	rs1021508	C	T	0.633	0.034	0.006	2.09E-09	65405	Fetal	PW & BW same direction
<i>PDE10A*</i>	6	166199513	rs6456014	C	A	0.582	0.030	0.006	4.42E-08	65405	Fetal	Predominantly or only PW
<i>ISPD</i>	7	16193877	rs7783810	C	T	0.422	0.039	0.006	1.85E-12	65405	Fetal	PW & BW same direction
<i>TBX20</i>	7	35282931	rs10486660	A	C	0.608	0.040	0.006	9.49E-13	65405	Fetal	PW & BW same direction
<i>YKT6</i>	7	44246271	rs138715366	C	T	0.991	0.202	0.035	7.91E-09	63786	Fetal & Maternal	PW & BW same direction
<i>ENTPD4</i>	8	23342043	rs6557677	T	A	0.166	0.044	0.007	2.66E-09	65405	Fetal	Predominantly or only PW
<i>SLC45A4</i>	8	142247979	rs12543725	G	A	0.585	0.032	0.006	9.20E-09	65405	Unclassified	PW & BW same direction
<i>KLF4</i>	9	110822658	rs1434836	A	G	0.575	0.035	0.006	2.87E-10	65405	Fetal	PW & BW same direction
<i>ADRB1</i>	10	115805056	rs1801253	C	G	0.743	0.052	0.006	8.06E-17	65405	Fetal	PW & BW same direction
<i>KCNQ1</i>	11	2839751	rs2237892	T	C	0.056	0.077	0.014	1.03E-08	48809	Fetal & Maternal	Predominantly or only PW
<i>SERPINA1</i>	14	94838142	rs112635299	T	G	0.024	0.149	0.019	1.42E-15	64541	Fetal	Predominantly or only PW
<i>FES/FURIN</i>	15	91428636	rs7177338	A	G	0.536	0.035	0.006	3.28E-10	65405	Unclassified	PW & BW same direction
<i>NR2F2</i>	15	96852638	rs55958435	A	G	0.713	0.042	0.006	6.82E-12	65405	Fetal	PW & BW same direction
<i>GPR139/GPRC5B</i>	16	20006986	rs57790054	G	A	0.302	0.035	0.006	5.54E-09	65405	Fetal	PW & BW same direction
<i>SLC6A2</i>	16	55717569	rs11866404	C	G	0.533	0.042	0.006	8.55E-14	65405	Fetal	Predominantly or only PW
<i>SLC7A5</i>	16	87882209	rs876987	G	A	0.306	0.038	0.007	1.24E-08	48809	Fetal	PW & BW opposite directions
<i>LOC339593</i>	20	11200008	rs6040436	T	C	0.444	0.054	0.006	1.55E-22	65405	Fetal	PW & BW same direction
<i>LOC339593*</i>	20	11428113	rs6078190	C	A	0.319	0.040	0.006	1.36E-11	65405	Fetal	Predominantly or only PW
Maternal												
<i>EBF1</i>	5	157808173	rs72804545	A	T	0.888	0.064	0.011	2.23E-08	41211	Maternal	PW & BW same direction
<i>LMO1</i>	11	8255408	rs2168101	C	A	0.696	0.047	0.008	2.13E-09	41356	Maternal	PW & BW same direction
<i>SLC38A4</i>	12	47180370	rs180435	C	G	0.190	0.051	0.007	1.68E-12	61153	Maternal	PW & BW same direction
<i>NLRP13</i>	19	56423893	rs303998	G	A	0.404	0.039	0.006	2.12E-11	61063	Maternal	PW & BW same direction
Paternal												
<i>EBF1</i>	5	158317602	rs75512885	T	A	0.925	0.080	0.015	4.96E-08	31714	Unclassified	PW & BW same direction
<i>LOC339593</i>	20	11207949	rs2207099	A	G	0.448	0.038	0.006	8.77E-10	52271	Fetal	PW & BW same direction

226
227
228
229
230
231
232
233
234
235

The lead SNP is given in the rsid column. Where PW loci fell within 500 kb of BW loci, locus names were given the name of the BW locus in Warrington et al.¹⁵ otherwise the locus was named by the nearest gene. Secondary signals at a locus are marked with an asterisk. Effect alleles are coded to correspond to increasing PW. Beta and SEs are given in SD units of PW. The subheadings under Locus Name indicate the GWAS analysis that the signal was identified in, and two last columns classify signals into fetal and/or maternal mode of association (using a weighted linear model¹⁵) and into whether effects were only/predominantly on PW, or also on BW. Abbreviations: Chr, chromosome; rsid, reference SNP cluster ID; EA, effect allele; OA, other allele; SE, standard error; P, P value; N, number; BW, birth weight; PW, placental weight.

236 **Resolving fetal and parental contributions to association signals**

237 Fetal genotype is correlated with both maternal and paternal genotype (each $r = 0.5$). While the fetal
238 genotype may influence PW directly, the maternal genotype itself may have effect *via* the intrauterine
239 environment. To calculate the SNP heritability of the maternal, paternal, and offspring contributions we
240 used a framework within genomic structural equation modelling (SEM)²⁰ developed by Moen et al.²¹
241 (Methods). We found evidence for substantial contributions from the fetal ($h^2=0.22$ (SE=0.03)) and
242 maternal ($h^2=0.12$ (SE=0.02)) genomes to variation in placental weight, and a small component from the
243 paternal genome ($h^2=0.06$ (SE=0.02))(Supplementary Table 9, Supplementary Fig. 3). We also found genetic
244 correlation between the three latent variables suggesting that the fetal effect on placental weight was
245 negatively correlated with both maternal and paternal effects, while maternal and paternal effects on
246 placental weight were positively correlated (Supplementary Table 9).

247
248 To estimate fetal-specific, maternal-specific, or paternal-specific effects on PW at each identified locus, we
249 first applied a weighted linear model (WLM)¹⁵ to the GWAS meta-analysis summary statistics. The WLM can
250 accurately approximate conditional effects (e.g. fetal effect conditional on any maternal effect, or vice
251 versa) in absence of genotyped mother-child pairs by incorporating results from all samples, even those
252 overlapping between the three GWAS meta-analyses (Methods), to maximize statistical power. We applied
253 formulations of the WLM allowing for non-zero paternal effects, or fixing the paternal effects to zero
254 (Supplementary Table 10). At the 41 association signals, we applied the classification method used for BW¹⁵
255 (Methods) to categorize the SNPs as having fetal or maternal effects. Hence, 26 SNPs were classified as
256 fetal only, four as maternal only, two as fetal and maternal with effects in opposite directions, and one as
257 fetal and maternal with effects in the same direction. We could not resolve the classification for the
258 remaining eight loci (Supplementary Table 10, Supplementary Fig. 4a, Supplementary Fig.4b).


259
260 We complemented the WLM analysis with within-family analyses in the child-mother-father trio subset
261 from the Norwegian Mother, Father, and Child Cohort (MoBa)²². First, the associations of fetal and parental
262 genotypes with PW were conditioned against each other ($n = 19,861$ independent trios,
263 Supplementary Table 10). There was good agreement between mode of association categories based on
264 WLM results and those from conditional analyses in trios. Taking advantage of the availability of phased
265 genotypes for MoBa children, we further decomposed the association signals into their mode of
266 transmission (*i.e.*, maternal transmitted, maternal non-transmitted, paternal transmitted, and paternal
267 non-transmitted alleles). Since several loci were already known to be associated with BW (see below), we
268 compared our results with a recent analysis of BW-mode of transmission¹⁶ (Supplementary Table 11). For
269 loci associated with both traits, effect size estimates and mode of transmission were consistent between
270 BW and PW analyses (Fig. 3a, Supplementary Fig. 5). Among the eight loci that remained unclassified after
271 WLM analysis of PW, five were identified previously in BW GWAS and classified as fetal¹⁶, and one was
272 classified as fetal and maternal with same direction of effect (Supplementary Table 11).

273
274 For the signal identified in the paternal GWAS near *EBF1* (rs75512885), our sample size did not allow
275 resolving the mode of association using WLM or parent-offspring trio analyses, but this variant is in
276 moderate LD with rs72813918 ($r^2 = 0.57$), classified previously as fetal for BW¹⁶ (Supplementary Table 11).
277 Colocalization analysis suggested that this signal for BW was independent of the nearby fetal association
278 signal for PW (rs67265526; posterior probability for independent signals > 0.99). The lead SNP of the other
279 paternal GWAS locus (rs2207099, near *LOC339593*) colocalized with the nearby fetal lead SNP (rs6040436;
280 posterior probability for shared association = 0.97) (Supplementary Table 7), and was therefore excluded
281 from subsequent analyses, leaving 40 independent association signals.

282 For all loci, we inspected the distance of the lead SNP to known imprinted genes according to
 283 www.geneimprint.com ([Supplementary Table 11](#)). Only one lead variant was found near imprinted genes;
 284 rs2237892 located in intron 10 of the imprinted gene *KCNQ1*. Indeed, the mode of transmission analysis in
 285 MoBa showed that the association with PW was only conferred by the maternally transmitted allele
 286 (Fig. 3b, [Supplementary Fig. 5](#)) consistent with the known maternal-only expression of *KCNQ1* and nearby
 287 *CDKN1* genes. This variant shows POE on type 2 diabetes risk²³, where the maternally inherited risk allele
 288 (C) corresponds to the maternally inherited PW-decreasing allele identified here. Another nearby variant,
 289 rs234864, has been reported¹⁶ as a maternally-transmitted effect only for BW. The very low LD ($r^2 = 0.05$)
 290 and very different minor allele frequencies (5.6% vs. 49.4%) between the two variants suggest that these
 291 may be independent signals, both imprinted (Fig. 3c). While the maternally transmitted allele of the BW
 292 variant rs234864 was strongly associated with both PW and BW in MoBa, the maternally transmitted allele
 293 of the PW variant rs2237892 showed directionally consistent, but weaker evidence of association with BW
 294 in MoBa (Fig. 3d). This is in agreement with the lower fetal effect size detected of rs234864 on BW in
 295 previous BW GWAS¹⁶ compared with the effect on PW ([Supplementary Table 11](#)).

296
297
298
299

Fig. 3: Resolving fetal and parental contributions to PW associations.



300
301
302
303
304
305

a, Effect size estimates divided by standard error in the mode of association analyses for the 41 association signals and the association of the maternal non-transmitted, maternal transmitted, paternal transmitted, and paternal non-transmitted alleles with standardized PW and BW adjusted for sex and gestational duration in MoBa, and with BW according to Juliusdottir *et al.*¹⁶ (a blank value indicates that no proxy was

306 found with $r^2 \geq 0.2$). **b**, Effect size estimates for standardized PW and BW adjusted for sex and gestational
307 duration for rs2237892 near *KCNQ1* in MoBa, thin and thick error bars respectively represent 95%
308 confidence intervals and one standard error on each side of the effect size estimate. **c,d**, Regional plots at
309 the *KCNQ1* locus, plotting the negative base 10 logarithm of the unadjusted *P*-value against genomic
310 location, for the maternal non-transmitted, maternal transmitted, paternal transmitted, and paternal non-
311 transmitted alleles in their association with standardized placental (**c**) and BW (**d**) adjusted for sex and
312 gestational duration in MoBa. The leading variants for PW and BW, rs2237892 and rs234864, are annotated
313 with a diamond and a circle, respectively. Points are colored according to their LD with rs2237892.
314 Abbreviations: MnT, maternal non-transmitted alleles; MT, maternal transmitted alleles; PT, paternal
315 transmitted alleles; PnT, paternal non-transmitted alleles.

316

317


318 **Correlations between PW and BW**

319 The strong phenotypic correlation reported between PW and BW^{12,14} was confirmed in the MoBa samples
320 in this study (Spearman's $r = 0.59$, adjusted for sex and gestational duration). We applied LD score
321 regression²⁴ to estimate genetic correlations with published BW association summary statistics¹⁵, analyzing
322 both main GWAS summary statistics, and WLM-adjusted estimates of the conditional fetal, maternal and
323 paternal effects (Fig. 4). Using WLM-adjusted effects for both PW and BW, the fetal and maternal genetic
324 correlations between PW and BW remained strong. We observed a negative genetic correlation between
325 fetal-specific effects on BW and maternal-specific effects on PW (Fig. 4c), whereas fetal-specific effects on
326 PW showed no genetic correlation with maternal-specific effects on BW (Fig. 4d). There was no genetic
327 correlation between paternal-specific effects on PW and either maternal- or fetal-specific effects on BW
328 after WLM-adjustment.

329

330

331 **Fig. 4: Genetic correlation between PW and BW.**
 332




333
 334
 335 a, Genetic correlation estimates for PW (current study - illustrated by circles or triangles with 95% CI) and
 336 BW (using 4 types of estimate) from Warrington *et al.*¹⁵. “Own birth weight” means fetal GWAS of
 337 birthweight, and “offspring birth weight” means maternal GWAS of offspring birth weight. Values are
 338 provided for fetal, maternal, and paternal effects before and after WLM adjustment. Error bars represent
 339 95% confidence intervals. Abbreviations: CI, confidence interval; Rg, genetic correlation; WLM, weighted
 340 linear model.

341
 342
 343 From the largest available GWAS of BW¹⁶, we selected BW loci within 500 kb of PW loci ([Supplementary](#)
 344 [Table 7](#)). Twenty-eight of the 40 independent PW signals were also reported for BW or had a BW lead SNP
 345 nearby. All these were within 100 kb of the PW lead SNP except rs876987 at *SLC7A5* (> 419 kb).
 346 Colocalization analysis suggested that 19 of these represent a shared underlying association (posterior
 347 probability for shared signal > 0.8), five signals were distinct (posterior probability for separate signals
 348 > 0.8), and the final four loci were uncertain (both posterior probabilities < 0.8).

349
 350 Given the large proportion of signals colocalizing with BW loci, we aimed to classify loci showing evidence
 351 of associations with both PW and BW from those showing only (or predominantly) evidence of association
 352 with PW, by comparing PW and BW effect estimates ([Supplementary Table 7](#), Methods). Twelve signals
 353 were classified as only or predominantly PW, and the remaining 28 were classified as both PW and BW
 354 signals, with one of these (near *SLC7A5*) showing opposite directions of effect both with $P < 0.05$. The
 355 results obtained from WLM-adjusted analysis were largely consistent (Fig. 5, [Supplementary Fig. 6](#),
 356 [Supplementary Table 7](#)). Thus, 12 of the 40 independent signals only influence PW, or have effects on PW
 357 that are larger than any estimated effect on BW (Table 1).
 358

359 **Fig. 5: Scatter plots comparing effect sizes from PW and BW GWAS for placental weight SNPs.**



360

361 Scatter plots comparing effect size estimates from the PW GWAS with those from the BW GWAS¹⁵. The left
 362 column shows fetal genome associations, and the right shows maternal. The top row shows SNPs classified
 363 as fetal only effects on PW (Supplementary Table 7). The middle row shows SNPs classified as maternal,
 364 or maternal and fetal, and the bottom row shows unclassified SNPs. SNPs with minor allele frequency below
 365 5% have been excluded to improve resolution. The full figure including the lower frequency SNPs is shown
 366 in Supplementary Fig. 6. Colors indicate the classifications, which are given in the key below the figure.
 367 Abbreviations: BW, birth weight; GWAS, genome-wide association study; PW, placental weight. Error bars
 368 represent 95% confidence intervals.
 369

370 **Connections to placental development and morphology, and transport of antibodies and amino acids**

371 To prioritize key tissues and cell types relevant to fetal genes implicated by our identified loci, we selected
372 the 31 protein-coding genes closest to the index SNP of the 32 loci identified in the fetal GWAS (i.e.
373 excluding *LOC339593*; Table 1) and examined their expression using tissue-specific mRNA abundance data
374 from the Human Protein Atlas and a scRNA-seq data set of over 70,000 single cells at the decidual-placental
375 interface in early pregnancy (Methods). Among 61 tissues, the 31 genes ranked higher in terms of mRNA
376 abundance than other genes in placenta ($P = 1.8 \times 10^{-4}$) (Supplementary Fig. 7, [Supplementary Table 12](#)). In
377 the single cell analysis among the 32 different cell types at the early maternal–fetal interface, expression of
378 the 31 genes ranked significantly higher than other genes in cell types of fetal origin, including fetal
379 endothelial cells ($P = 6.2 \times 10^{-5}$) and syncytiotrophoblasts ($P = 1.9 \times 10^{-4}$), but they also ranked higher in
380 maternal innate lymphocyte cells ($P = 1.2 \times 10^{-3}$) (Supplementary Fig. 8, [Supplementary Table 12](#)).

381
382 To further investigate associations between PW loci and gene expression or methylation in placental tissue,
383 we queried lead PW SNPs (and their proxies $r^2 \geq 0.8$) against eQTL data from placenta in the Rhode Island
384 Child Health Study dataset²⁵. Lead PW SNPs tagged placental eQTL at four loci (*HSPA4*, *TBX20*, *SLC7A5*,
385 *JAG1*) ([Supplementary Table 7](#)). We additionally investigated whether any of the 40 independent lead SNPs
386 were associated with placental DNA methylation at CpG sites within 0.5 Mb. Using Gen3G data^{26,27}, we
387 identified placental meQTLs at 21 of the 40 independent signals ($FDR \leq 0.05$ extrapolated from the
388 genome-wide beta distribution by TensorQTL; Supplementary Fig. 8). Among the 21 lead SNPs with
389 identified meQTLs, individual SNPs were associated with placental DNA methylation at up to 15 CpG sites
390 (Supplementary Fig. 9). [Supplementary Table 7](#) shows meQTLs with lowest P -value for each lead SNP.

391
392 We combined the placental expression and methylation data with further look-ups of lead PW SNPs in
393 available GWAS of gene expression, plasma protein levels, diseases and traits ([Supplementary Tables 7, 13](#),
394 [14, 15](#)). These searches implicated several candidate genes and potential biological insights. For example,
395 the PW-raising allele of rs723177 at the fetal *RPL31P11* locus (Supplementary Fig. 2a) is an eQTL and pQTL
396 for *FCGR2A* and *FCGR2B* (receptors for the Fc region of IgG complexes) and associates with higher plasma
397 protein levels ([Supplementary Tables 14, 15](#)), suggesting a potential role in maternal antibody transfer
398 across the placenta²⁸. The lead variant rs723177 is also the strongest placental meQTL in the region at the
399 CpG site cg27514565 (overlapping DNase I Hypersensitive Sites [DHS] for primitive/embryonic and
400 myeloid/erythroid tissues) located between *FCGR2C* and *FCGR3B*, and two meQTL (at cg14354529 and
401 cg15531363) overlapping with trophoblast-specific DHS located downstream of *FCRLA* and *FCRLB*
402 (Supplementary Fig. 6). Associations at lead SNP rs10486660, at another fetal locus, suggest a role for this
403 locus in placental morphology: the SNP is intragenic in the T-box transcription factor gene, *TBX20*
404 (Supplementary Fig. 2a) and marks an eQTL for *TBX20* in placenta ([Supplementary Table 7](#)). Approximately
405 50% of *TBX20* placental expression is found in trophoblast cells²⁹, and *TBX20*-null mice are likely to show
406 abnormal placental morphology compared to wild-type mice³⁰. Third, the lead SNP rs112635299 is in LD
407 ($r^2 = 1.0$) with rs28929474, a missense variant in the serpin peptidase inhibitor gene *SERPINA1*
408 (Supplementary Fig. 2a). The SNP is associated with several traits, including levels of >20 circulating plasma
409 proteins³¹ ([Supplementary Table 15](#)) and the cause of autosomal recessive alpha-1 antitrypsin deficiency³².
410 Within the placenta, *SERPINA1* expression regulates expression of inflammatory cytokines and serine
411 protease *HTRA1*-induced trophoblast invasion through induction of endoplasmic reticulum stress³¹. Finally,
412 lead fetal SNP, rs876987, being the only variant showing an inverse effect on PW relative to BW, is
413 intragenic in *SLC7A5*, which encodes solute carrier family 7 member 5 (Supplementary Fig. 2a). The
414 heterodimer encoded by *SLC7A5* and *SLC3A2* is a sodium-independent, high-affinity amino acid exchanger
415 over membranes of several organs and is responsible for uptake of essential amino acids in placenta. Lead

416 variant rs876987 is an eQTL for *SLC7A5* in placenta and a meQTL for 15 CpG sites, with the strongest
417 association detected at cg03408354 ($P = 4.7 \times 10^{-49}$; located in intron 7 of *SLC7A5*) ([Supplementary Table 7](#);
418 [Supplementary Fig. 9d](#)).

419
420

421 **PW and pregnancy complications including preeclampsia**

422 We tested whether the 40 independent lead SNPs were associated with pregnancy and perinatal traits,
423 using published GWAS summary statistics for nausea and vomiting of pregnancy or hyperemesis
424 gravidarum³³, preeclampsia³⁴, gestational duration³⁵, miscarriage (recurrent and spontaneous)³⁶, and ten
425 cytokines assayed from neonatal blood spots³⁷. The SNPs showed more associations with nausea and
426 vomiting of pregnancy (maternal genotype effects), and with gestational duration, preeclampsia, and
427 neonatal IgA levels (all fetal genotype effects) than expected under the null distribution ([Supplementary](#)
428 [Fig. 10](#), [Supplementary Table 16](#))^{35,36}. Scatter plots of effect sizes ([Supplementary Fig. 11](#)) suggested that
429 fetal alleles predisposing to higher PW tended to associate with higher odds of preeclampsia and a shorter
430 gestational duration. To formally test the effect of fetal PW raising alleles on preeclampsia and gestational
431 duration, we performed Mendelian randomization (MR) analyses. These analyses showed that fetal genetic
432 predisposition to a higher PW raises the risk of preeclampsia (OR 1.72 [95% CI: 1.19 - 2.47] per 1 SD higher
433 fetal genetically predicted PW, $P = 6 \times 10^{-3}$), and shortens gestational duration (1.9 days
434 [95% CI: 0.74 - 3.12] shorter per 1 SD higher fetal genetically predicted PW, $P = 3 \times 10^{-3}$) ([Supplementary](#)
435 [Table 17](#), [Supplementary Fig. 12](#)). We were unable to test causal relationships between fetal genetically
436 predicted PW and nausea and vomiting of pregnancy or IgA, because only maternal effect estimates were
437 available for the nausea and vomiting of pregnancy outcome³³ and only unadjusted fetal effect estimates
438 for IgA³⁷. The gestational duration results were similar to those previously seen for BW³⁸, where fetal
439 genetic predisposition to higher BW is associated with shorter gestation, implying a general effect of
440 fetoplacental growth³⁹. However, known BW-associated SNPs¹⁵ with fetal only effects showed little
441 evidence of association in the fetal GWAS of preeclampsia ([Supplementary Fig. 9t](#)), contrary to PW-
442 associated SNPs with fetal only effects ([Supplementary Fig. 9u](#)). MR analysis did not support a causal
443 relationship between fetal genetic predisposition to higher BW and odds of preeclampsia ($P = 0.6$;
444 [Supplementary Table 17](#), [Supplementary Fig. 12](#)), suggesting that the increase in preeclampsia risk is more
445 specific to placental growth.

446
447

448 **Maternal and fetal characteristics and their effects on PW**

449 We selected key maternal and fetal traits known to influence BW^{15,16} and used genetic instruments to
450 assess whether there were similar causal relationships with PW.

451

452 **Maternal glucose, fetal insulin and PW**

453 Fetal insulin is a major determinant of fetal growth. Lower fetal insulin secretion due to rare fetal *GCK*
454 mutations lead to reduced BW and PW compared with siblings without mutations^{40,41}. To investigate the
455 role of fetal insulin on PW in the general population, we used three SNP-sets in MR analyses: (i) 33 fasting
456 glucose SNPs (maternal glucose crosses the placenta stimulating fetal insulin secretion; (ii) 18 insulin
457 disposition index SNPs (estimated by insulin secretion multiplied by insulin sensitivity commonly used as a
458 proxy for β -cell function); and (iii) 53 BMI-adjusted fasting insulin SNPs (insulin resistance proxy in adults)
459 ([Supplementary Table 18](#))¹⁵. We used WLM estimates to ensure that maternal effects were adjusted for
460 fetal effects, and vice versa. A genetic instrument representing 1 SD (0.4 mmol/l) higher maternal fasting
461 glucose level was associated with a 47.4-g (95% CI: 23.7 - 71.2 g) higher placental weight ($P = 4.46 \times 10^{-4}$;

462 Fig. 6; [Supplementary Table 18](#)). In addition, a 1-SD genetically higher fetal disposition index was associated
463 with a 13.9-g (1.2 - 26.6) higher PW. Alleles that raise insulin secretion tend to lower glucose levels, and this
464 was reflected in the opposite direction of the effect estimates for maternal disposition index (Fig. 6;
465 [Supplementary Table 18](#)). The causal effect estimate for fetal insulin resistance was directionally consistent
466 with causing lower PW, but the 95% CI crossed the null. These analyses support a role for insulin produced
467 by the fetus, either directly or indirectly, in regulating growth of the placenta, providing a key link between
468 fetal insulin and placental growth.

469

470 **Height and PW**

471 Our analyses showed that both fetal and maternal genetic predisposition to a greater adult height were
472 associated with greater PW, consistent with previous associations with higher BW and length^{15,16}. A 1-SD
473 (approx. 6 cm) higher genetically predicted adult height in the fetus was associated with a 12.1-g
474 (95% CI: 7.1 - 17.2) higher PW ($P = 2.88 \times 10^{-6}$; Fig. 6; [Supplementary Table 18](#)) and a 1-SD higher maternal
475 height was associated with a 4.7-g (95% CI: 0.8 - 8.7) higher PW, independent of direct fetal effects
476 ($P = 1.89 \times 10^{-2}$; Fig. 6; [Supplementary Table 18](#)). These findings further emphasize key contributions of
477 common fetal genetic factors to the close relationship between fetal and placental growth.

478

479 **Blood pressure and PW**


480 Higher maternal blood pressure in pregnancy is associated with reduced fetal growth⁴². To estimate the
481 causal effect of maternal SBP or DBP on PW (adjusting for any direct fetal genetic effects), we used 68
482 known systolic blood pressure (SBP)-associated variants and 71 known diastolic blood pressure (DBP)-
483 associated variants in two-sample MR analyses. We found no evidence of a causal effect of either maternal
484 SBP ($P = 0.23$) or maternal DBP ($P = 0.91$; Fig. 6; [Supplementary Table 18](#)). However, analyses using direct
485 fetal genotype effects (adjusted for maternal genotype effects) suggested that a 10-mmHg genetically
486 higher DBP in the fetus caused a 19.0-g (95% CI: 3.8 - 34.3 g) lower PW, with a weaker effect of SBP in the
487 same direction (9.5 g [95% CI: 0.5 - 19.7 g]; Fig. 6; [Supplementary Table 18](#)). Previous MR analyses of fetal
488 blood pressure effects on BW have been inconsistent: those that used similar methods^{15,43} to the current
489 analyses found no fetal effects, while others using transmitted and non-transmitted alleles^{16,38} supported
490 fetal genetic predisposition to higher SBP being causally related to lower BW. Our findings for PW are
491 similar to the latter.

492

493

494

495 **Fig. 6: MR analyses testing effects of maternal exposures (and fetal genetic predisposition to**
 496 **those exposures) on PW**
 497



498
 499
 500
 501
 502
 503
 504
 505
 506
 507

Results of two-sample MR analyses estimating the causal effects of maternal height, glycemic traits and blood pressure on PW, and the effects of fetal genetic predisposition to the same traits on PW. Maternal WLMs are adjusted for effects of the fetal genotypes, and fetal WLM analyses are adjusted for the effects of the maternal genotypes. Abbreviations: DBP, diastolic blood pressure; meta, meta analysis; SBP, systolic blood pressure; WLM, weighted linear model. Units for exposures are: height (SD), fasting glucose (SD), disposition index (SD), fasting insulin (SD), SBP (10 mmHg), DBP (10 mmHg). Causal estimates are g of placental weight per unit exposure.

508 **PW and later neuropsychiatric traits**

509 The role of placenta in neurodevelopment and risk of later psychiatric disease in the offspring is a growing
510 research field. Using data from the Initiative for Integrative Psychiatric Research (iPSYCH) cohort ($n =$
511 100,094), we analyzed observed fetal polygenic scores (PGS) for PW in groups of individuals who later
512 developed neuropsychiatric disease. As expected, higher deciles in the PGS distribution corresponded to
513 higher observed PW in a population representative sample, and we also observed similar patterns of
514 association with PW in groups of individuals with autism spectrum disorder (ASD), attention
515 deficit/hyperactivity disorder (ADHD), affective disorders, and schizophrenia ([Supplementary Fig. 13](#)).
516 Logistic regression of each disease on fetal PGS for PW did not show any association, although there was a
517 nominally significant association between higher observed PW and reduced risk of ADHD ($P = 0.0247$;
518 [Supplementary Fig. 14](#)).

519

520


521

522 Discussion

523 In this first GWAS of PW, we identify 40 independent association signals. These partially overlap with
524 known BW loci, but 12 PW signals are related predominantly or only to PW, with connections to placental
525 development and function. We observe a maternal POE near *KCNQ1*. Moreover, we find that fetal
526 genetically mediated higher PW raises preeclampsia risk and shortens gestational duration, and we
527 demonstrate a role for fetal insulin in regulating placental growth. Fig. 7 summarizes central results of the
528 study.

529

530 **Fig. 7: Overview of main study results.**



531

532

533

534 A salient feature of this study was the ability to address mode of association questions through analyses of
535 fetal and parental genomes, application of WLM approaches, and analyses of almost 20,000 child-mother-
536 father trios from the MoBa study. There was a clear predominance of fetal effect signals among the
537 genome-wide significant loci, and fetal SNP heritability was almost double that of maternal SNP heritability
538 (Supplementary Fig. 5). A total of 26 signals were classified as fetal only, and a further 3 as fetal and
539 maternal. However, there were 4 loci that showed no fetal effect, and instead represent indirect maternal
540 genetic effects acting on PW via the intrauterine environment. For loci also known to be associated with
541 BW, our mode of association results were in good agreement with a previous classification¹⁶.

542 Investigations using MoBa trio data found a pronounced POE signal near *KCNQ1* carried by the maternally
543 transmitted allele, in agreement with previously observed silencing of the paternal alleles of *KCNQ1* and
544 the nearby *CDKN1C* gene. Notably, based on WLM analysis, we had classified the *KCNQ1* locus as having
545 maternal and fetal effects in the same direction. Although the WLM may improve power to distinguish
546 between maternal and fetal effects in available samples, family studies are still key to attaining clarity
547 about how associations with neonatal phenotypes may arise, through fetal effects, POEs, maternal effects,
548 or a combination. The *KCNQ1* finding has implications in fetal and placental growth through at least two
549 pathways⁴⁴. Placenta cells have a unique epigenetic profile that regulates its transcription patterns that
550 may be associated with adverse pregnancy outcomes if disturbed. Beckwith-Wiedemann syndrome is an
551 overgrowth syndrome with elevated PW and BW⁴⁴. Approximately 50% of these patients have lost
552 maternal-specific methylation at the putative Imprinting Control Region 2 (*ICR2*) within intron 10 of *KCNQ1*
553 that is also the transcriptional start site of the regulatory long non-coding RNA *KCNQ1OT1*⁴⁵ controlling
554 expression of *CDKN1C* and *KCNQ1*. The location of the lead signal, rs2237892, to this region suggests it
555 influences PW through an effect on methylation at *ICR2* in the placenta. Known associations between SNP
556 rs2237892 and altered insulin secretion^{46,47} support a role for fetal insulin in mediating the association with
557 PW. Additionally, placental DNA methylation at *KCNQ1* has been associated with maternal insulin
558 sensitivity⁴⁸, influencing maternal glucose availability across the placenta, and stimulating fetal insulin thus
559 leading to fetal and placental growth.

560
561 Our results support a role for fetal genetic factors that predispose to a higher PW in raising preeclampsia
562 risk: for every 1-SD higher genetically mediated PW, there was a more than 1.5-fold higher odds of
563 preeclampsia. Preeclampsia is a complication that occurs in 3-5% of pregnancies^{4,49}, but is poorly
564 understood. The causal relationship we observed appears specific to placental growth as there was no
565 similar effect of fetal genetic predisposition to higher BW. This finding is initially counter-intuitive,
566 considering that preeclampsia is often linked with fetal growth restriction. However, the relationship
567 between preeclampsia and placental weight is not consistent: early-onset preeclampsia, which is likely
568 caused by defective placentation, is frequently associated with fetal growth restriction and low placental
569 weight^{50,51}, while the more common, “late-onset” or “term” preeclampsia (delivery in or after gestational
570 week 37) has been associated observationally with both lower and higher PW⁵¹. Late-onset preeclampsia is
571 thought to result largely from interactions between aging of the placenta and a maternal genetic
572 susceptibility to cardiometabolic diseases⁵⁰, but there is evidence that fetal trophoblast function is also
573 important: the common genetic contributor to preeclampsia at the *FLT1* locus (lead SNP rs4769613) is fetal.
574 Fetal *FLT1* likely mediates maternal endothelial dysfunction, but the variant was not associated with PW in
575 our study, or with BW ($P > 0.05$)¹⁵. Our finding is supportive of a role for increased fetoplacental demands,
576 which may result in uteroplacental mismatch, leading to late-onset preeclampsia⁴ and supports the role of
577 fetally-mediated placental mechanisms in contributing to this condition.

578
579 Using PW as a proxy for placental growth had the advantage to reach the large sample size of this study,
580 leveraging routine records in birth registers, and thereby yielding sufficient statistical power for discovery.
581 One limitation, however, is that PW measured after delivery only crudely proxies placental growth and
582 does not directly capture placental insults or other indications of placental dysfunction. Our study would
583 therefore be complemented well by other approaches, e.g., involving single-cell transcriptomics of
584 placental cells early in pregnancy¹⁹, characterization of placental mosaicism⁵², sequencing of cell-free RNA
585 transcripts of placental origin in maternal circulation during pregnancy⁵³, and RNA sequencing of placental
586 samples without and with pregnancy complications^{25,54}. Furthermore, while our results point to plausible
587 candidate genes (e.g., *FCGR2A*, *FCGR2B*, *TBX20*, *SERPINA1*, *SLC7A5*) and potential effects on placental

588 development and morphology, and transport of antibodies and amino acids, follow-up studies are required
589 to establish causal links and to illuminate mechanisms related to placental growth.

590

591 Our study complements large-scale GWAS of BW. While genetic correlation and colocalization analyses
592 revealed an overlap between signals associated with PW and BW, there were also notable differences.
593 Twelve loci were classified as only or predominantly PW, and one signal showed opposite directions of
594 effects between PW and BW, emphasizing the complexity of common and distinct genetic regulation and
595 physiological processes affecting placental and fetal growth. Thus, our findings provide an improved
596 understanding of the role of placenta for fetal growth and biological processes and complications such as
597 gestational duration and preeclampsia. Future research may focus on additional proxies for placental
598 function and environmental influences, as well as the role of placenta for later-life health outcomes.

599

600

601 **Methods**

602 **Study cohorts and phenotype handling**

603 Studies of individuals from European populations conducted genome-wide association analysis (GWAS) of
604 placental weight as part of the EGG (Early Growth Genetics) Consortium. Where data was available,
605 multiple births, congenital anomalies and babies born before 37 completed weeks of gestation or after 42
606 weeks and 6 days of gestation were excluded. Additionally, placental weight values < 200 g or > 1,500 g, or
607 greater than five standard deviations from the mean were excluded. Placental weight was Z-score
608 transformed for analysis. Details for phenotype exclusions, data collection, sample size, mean placental
609 weight and gestational age for each cohort can be found in [Supplementary Tables 1, 3, 5](#).

610

611 **Fetal, maternal, and paternal meta-analyses of PW GWAS**

612 We performed separate GWAS to test associations between PW and fetal, maternal, and paternal
613 genotypes, as detailed in equations (1) to (3).

$$614 \quad pw \sim \text{child} + \text{sex} (+ \text{gestational age}) + \text{study specific covariates} \quad (1)$$

$$615 \quad pw \sim \text{mother} + \text{sex} (+ \text{gestational age}) + \text{study specific covariates} \quad (2)$$

$$616 \quad pw \sim \text{father} + \text{sex} (+ \text{gestational age}) + \text{study specific covariates} \quad (3)$$

617 where 'pw' refers to the standardized PW, and 'child', 'mother' and 'father' refer to the number of tested
618 alleles (as genotype probabilities) for a given variant in the child, mother, and father genomes, respectively.

619 Analyses were conducted twice, once adjusting for sex and gestational age and once adjusting for sex only.
620 Adjustment was also made for ancestry principal components, and the number of principal components
621 included was determined on a per-cohort basis. Genotypes were imputed to the HRC reference panel in
622 most studies, with exceptions noted in [Supplementary Tables 2, 4, 6](#). Details of imputation and analysis for
623 individual studies are shown in [Supplementary Tables 2, 4, 6](#). Association results from fetal, maternal, and
624 paternal GWASs using both adjustment strategies were combined separately in fixed-effects meta-analyses
625 implemented in METAL⁵⁵, resulting in six meta-analyses. Meta-analyses were performed independently by
626 two analysts. SNPs were excluded if they were present in fewer than two studies or the number of
627 individuals for the SNP was < 5,000. Genome-wide significant loci were defined as regions with one or more

628 SNP with $P < 5 \times 10^{-8}$, and these SNPs were defined as belonging to different loci if the distance between
629 them was > 500 kb. The lead SNP at each locus was the one with the smallest P -value. Secondary signals
630 within each locus were identified using approximate conditional and joint multiple-SNP (COJO) analysis
631 performed using GCTA-COJO⁵⁶. Independent SNPs were defined as those with conditional $P < 5 \times 10^{-8}$. The
632 linkage disequilibrium reference panel was made up of 344,241 individuals from the UK Biobank defined as
633 having British ancestry⁵⁷.

634

635 **Genomic SEM**

636 To calculate the SNP heritability of the maternal, paternal and offspring contributions we used a framework
637 within genomic SEM²⁰ developed by Moen et al²¹. In short the genomic SEM method²⁰ involves two stages.
638 In the first stage, LD score regression methods using pre-computed LD Scores from a European population
639 provided by the original developers of LD score regression^{24,58} are applied to GWAS summary results
640 statistics to estimate the genetic variance of each trait, and the genetic covariance between traits. In the
641 second stage of genomic SEM, a user-defined SEM is fit to the genetic covariance matrix and parameters
642 and their standard errors are estimated.

643 The genomic structural equation model we used to partition genetic covariances into maternal and
644 offspring components is displayed in Supplementary Fig. 15. Results from the three placenta weight GWAS
645 (squares) were modelled in terms of latent maternal, paternal and offspring genetic variables (circles). The
646 lower part of this model reflects simple biometrical genetics principles (i.e. the fact that offspring and
647 maternal genome are correlated 0.5) and consists of path coefficients fixed to the value one or one half.
648 The top half of the model consists of free parameters requiring estimation - three SNP heritabilities (one for
649 each trait), and three genetic covariances between the variables, representing commonalities in genetic
650 action across the maternal, paternal and offspring genomes²¹.

651 It is important to realize that fitting a complicated SEM like the one in Supplementary Fig. 15 is necessary to
652 obtain asymptotically unbiased estimates of SNP heritabilities and genetic correlations. The reason is that
653 GWAS of perinatal traits represent a complicated mixture of maternal, paternal and offspring genetic
654 effects. Our SEM disentangles these effects from each contributing GWAS. In contrast, the model
655 underlying LD Score regression makes no allowance for this complication, and so naïve use will lead to
656 biased estimates of SNP heritability and genetic correlations containing an unknown mixture of maternal,
657 paternal and fetal effects²¹. Summary results statistics files from the GWASs described above were
658 combined using genomic SEM²⁰. The software was set to not exclude INDELS.

659

660 **Partitioning fetal, maternal, and paternal effects, and allele transmission analysis**

661 Partitioning fetal, maternal, and paternal effects was performed from the summary statistics obtained from
662 the GWAS (equations (1) to (3)) using a weighted linear model (WLM) similar to that applied in Warrington
663 et al., extended to include paternal data and overlap in individuals between GWASs. The estimates of
664 partitioned fetal, maternal, and paternal effects ($\hat{\eta}_c$, $\hat{\eta}_m$, and $\hat{\eta}_f$ respectively), estimated from the GWAS
665 estimates ($\hat{\beta}_c$, $\hat{\beta}_m$, and $\hat{\beta}_f$ respectively) are

$$666 \quad \hat{\eta}_c = 2\hat{\beta}_c - \hat{\beta}_m - \hat{\beta}_f \quad (4)$$

$$667 \quad \hat{\eta}_m = -\hat{\beta}_c + \frac{3}{2}\hat{\beta}_m + \frac{1}{2}\hat{\beta}_f \quad (5)$$

668
$$\hat{\eta}_f = -\hat{\beta}_c + \frac{1}{2}\hat{\beta}_m + \frac{3}{2}\hat{\beta}_f. \quad (6)$$

669 To account for sample overlap between GWASs, the covariance in estimates of the regression coefficients
670 has the form

671
$$\hat{\sigma}_{ij} = \frac{N_{sij}}{\sqrt{N_i N_j}} \hat{\rho}_{ij} \sqrt{\hat{\sigma}_i^2 \hat{\sigma}_j^2} \quad (7)$$

672 where N_{sij} is the number of individuals contributing to both analyses, N_i is the number of individuals
673 contributing to analysis i , $\hat{\rho}_{ij}$ is the correlation between the estimates $\hat{\beta}_i$ and $\hat{\beta}_j$ in the overlapping
674 samples, and $\hat{\sigma}_i$ is the standard error of $\hat{\beta}_i$. The term $\frac{N_s}{\sqrt{N_i N_j}} \hat{\rho}_{ij}$ can be estimated as the intercept of a
675 bivariate LDscore regression²⁴. Standard errors for the partitioned effects are then estimated as

676
$$\hat{\sigma}_{\eta c}^2 = 4\hat{\sigma}_c^2 + \hat{\sigma}_m^2 + \hat{\sigma}_f^2 + 2 \frac{N_{smf}}{\sqrt{N_m N_f}} \hat{\rho}_{mf} \sqrt{\hat{\sigma}_m^2 \hat{\sigma}_f^2} - 4 \frac{N_{scm}}{\sqrt{N_c N_m}} \hat{\rho}_{cm} \sqrt{\hat{\sigma}_c^2 \hat{\sigma}_m^2} - 4 \frac{N_{scf}}{\sqrt{N_c N_f}} \hat{\rho}_{cf} \sqrt{\hat{\sigma}_c^2 \hat{\sigma}_f^2} \quad (8)$$

677
$$\hat{\sigma}_{\eta m}^2 = \frac{9}{4}\hat{\sigma}_m^2 + \hat{\sigma}_c^2 + \frac{1}{4}\hat{\sigma}_f^2 - \frac{N_{scf}}{\sqrt{N_c N_f}} \hat{\rho}_{cf} \sqrt{\hat{\sigma}_c^2 \hat{\sigma}_f^2} - 3 \frac{N_{scm}}{\sqrt{N_c N_m}} \hat{\rho}_{cm} \sqrt{\hat{\sigma}_c^2 \hat{\sigma}_m^2} + \frac{3}{2} \frac{N_{smf}}{\sqrt{N_m N_f}} \hat{\rho}_{mf} \sqrt{\hat{\sigma}_m^2 \hat{\sigma}_f^2} \quad (9)$$

678
$$\hat{\sigma}_{\eta f}^2 = \frac{9}{4}\hat{\sigma}_f^2 + \hat{\sigma}_c^2 + \frac{1}{4}\hat{\sigma}_m^2 - \frac{N_{scm}}{\sqrt{N_c N_m}} \hat{\rho}_{cm} \sqrt{\hat{\sigma}_c^2 \hat{\sigma}_m^2} - 3 \frac{N_{scf}}{\sqrt{N_c N_f}} \hat{\rho}_{cf} \sqrt{\hat{\sigma}_c^2 \hat{\sigma}_f^2} + \frac{3}{2} \frac{N_{smf}}{\sqrt{N_m N_f}} \hat{\rho}_{mf} \sqrt{\hat{\sigma}_m^2 \hat{\sigma}_f^2}. \quad (10)$$

679 P-values are calculated from WLM estimates using a Z-test, with test statistic

680
$$Z = \frac{\hat{\eta}_i}{\hat{\sigma}_i}. \quad (11)$$

681

682 To complement this analysis, we utilized the independent child-mother-father trios available in MoBa to
683 perform conditional analyses where the association of fetal and parental genotypes with PW are
684 conditioned against each other, as detailed in equation (12).

685
$$pw \sim \text{child} + \text{mother} + \text{father} + \text{sex} + \text{gestational age} + \text{study specific covariates} \quad (12)$$

686 In this set of independent trios, using the phasing of the children's genotypes, we inferred the parent-of-
687 origin of the genotyped alleles as done by Chen *et al.*³⁸. We then studied the association of the PW with
688 maternal and paternal transmitted and non-transmitted alleles, as detailed in equation (13).

689
$$pw \sim \text{mnt} + \text{mt} + \text{pt} + \text{pnt} + \text{sex} + \text{gestational age} + \text{study specific covariates} \quad (13)$$

690 Where 'mnt' and 'mt' refer to the maternal non-transmitted and transmitted alleles, respectively; and
691 similarly, 'pt' and 'pnt' refer to the paternal transmitted and non-transmitted alleles, respectively.

692 To estimate the significance of effects mediated by the maternal transmitted only, and hence test for
693 parent-of-origin effects, we conditioned it on the genotypes of the child, mother, and father for the same
694 variant, as detailed in equation (14).

695
$$pw \sim \text{mt} + \text{child} + \text{mother} + \text{father} + \text{sex} + \text{gestational age} + \text{study specific covariates} \quad (14)$$

696 Where variables are coded as in equations (13) and (14). Note that trio and haplotype analyses in MoBa
697 were conducted on hard-called genotypes. Sex, gestational age, and intercept were included in the model
698 as well as study specific covariates, *i.e.*, ten principal components and genotyping batches. The share of

699 Mendelian errors was estimated using trios presenting at least a homozygous parent. If a variant presented
700 more than 50 % Mendelian errors, children alleles were swapped. All estimates are provided in
701 [Supplementary Table 11](#).

702 To classify SNPs as either fetal, maternal or paternal, we used similar criteria to those used previously for
703 BW SNPs¹⁵. We classified SNPs into three categories: (1) Fetal only: the P value for the fetal estimate is
704 lower than a Bonferroni corrected threshold ($0.05/37 = 0.00132$), and the 95 % CI surrounding the estimate
705 does not overlap the 95 % CI for the maternal estimate; (2) Maternal only: the P value for the maternal
706 estimate is lower than a Bonferroni corrected threshold (0.00132), and the 95 % CI surrounding the
707 estimate does not overlap the 95 % CI for the fetal estimate; and (3) Maternal and Fetal: the P value for
708 both the maternal and fetal association estimates were less than the Bonferroni corrected threshold
709 (0.00132). If a SNP did not fit any of these criteria it was marked as “unclassified”.

710

711 **Assessing colocalization of fetal, maternal or paternal association signals**

712 To further supplement the aforementioned classifications, we performed colocalization analysis to
713 determine overlap between GWAS signals from fetal, maternal, and paternal meta-analyses using the R
714 library ‘coloc’⁵⁹ with the default prior probability for colocalization. Signals were defined as colocalising if
715 the posterior probability of shared association signals (P4) was > 0.8 , distinct if the posterior probability of
716 independent signals (P3) was > 0.8 , and undetermined if neither P3 or P4 was > 0.8 .

717

718 **LD score regression**

719 To estimate the genetic correlation between PW and BW, linkage disequilibrium score regression^{24,58} was
720 performed using summary statistics from gestational age and fetal sex adjusted analyses and BW summary
721 statistics taken from Warrington *et al*¹⁵. Estimates for the results from the meta-analyses and WLM for both
722 PW and BW were calculated for each of the fetal, maternal and paternal genomes.

723

724 **Testing whether lead PW SNPs were also associated with BW**

725 Colocalization analysis was again utilized to determine whether PW loci close to those previously identified
726 in GWAS of BW represent the same association signal, using the same colocalization methods as above.

727 To classify SNPs as placental weight or BW, we calculated the 95 % CI in SD units for the PW lead SNP for
728 both PW and BW. We then compared the 95% CIs; if these 95% CIs did not overlap the SNP was classified as
729 “predominantly or only PW” unless either BW association (fetal or maternal) was in the opposite direction
730 to the PW association and its associated P value was < 0.05 , in which case it was classified as PW and BW in
731 opposite directions. SNPs whose 95% CIs for PW and BW overlapped were classified as “PW and BW same
732 direction”.

733

734 **Enrichment analysis using tissue-specific mRNA expression and scRNA data**

735 We tested enrichment of expression of the PW associated genes in specific tissues or cell-types by
736 comparing the ranks of gene expression across different tissue or cell-types (Supplementary Fig. [16](#)). This

737 method involved two steps: *first*, the tissue or cell-type specific expression levels from a reference
738 expression data set were rank normalized across all tissues or cell-types for each gene; *second*, for a
739 particular tissue or cell-type, expression enrichment of the test genes were compared against all other
740 genes by the Wilcoxon rank-sum test. We used 31 protein-coding genes close to the index SNPs of the 32
741 PW-associated loci identified in the fetal GWAS (First section of Table 1; the *LOC339593* locus was not
742 included because no protein-coding gene nearby). For the enrichment analysis in specific tissues, we used
743 tissue-specific mRNA expression data from the Human Protein Atlas (RNA consensus tissue gene data)²⁹.
744 For the enrichment analysis in different cell-types, we used the scRNA-seq data of about 70,000 single cells
745 at the decidual-placental interface in early pregnancy¹⁹. Cell-type specific gene expression of each gene was
746 evaluated by percentage of cells with detectable scRNA reads. Significance levels for this enrichment
747 analysis were Bonferroni corrected by number of tissues ($n = 61$) or cell-types ($n = 32$).

748

749 **Identification of placental meQTL**

750 Using the 41 SNPs identified in the discovery meta-analyses GWASes of PW, we conducted placental
751 methylation QTL (methQTL) analysis in 395 participants with European ancestry from the Canadian cohort
752 of the study 'Genetics of Glucose Regulation in Gestation and Growth' (Gen3G)^{26,27}. We measured DNA
753 methylation using Illumina EPIC arrays from samples collected in the fetal-facing side of placenta. We
754 conducted DNA methylation data processing, normalization, and cell type composition estimation as
755 previously described²⁶. Whole genome sequencing data were processed with the DNA-Seq v3.1.4 pipeline
756 from GenPipes⁶⁰ based on BWA_mem and GATK best practices to identify high quality SNPs on GRCh37
757 through joint genotyping over all samples. SNPs with a call rate above 20%, Hardy-Weinberg equilibrium p-
758 value above 1e-6 and minor allele counts above 10 were included.

759

760 Methylation QTL were identified using beta values of 681 795 CpGs with TensorQTL⁶¹ in a cis-window of 0.5
761 Mb and the following covariates: four genotype PCs, fetal sex and cell type composition (estimates based
762 on DNA methylation). In order to correct for the multiple CpGs tested genome-wide, a FDR threshold of \leq
763 0.05 was applied on the q-values measured from the p-values extrapolated from the beta distribution by
764 TensorQTL.

765

766 **Mapping to pathways and traits**

767 Variants classified as PW through the SNP classification of PW or BW, were investigated further to identify
768 relevant pathways and related biology. Systematic look-ups using [Open Targets Platform](#), [The Human Protein Atlas](#), and [International Mouse Phenotyping Consortium](#). Each variant was assessed for which gene
769 it is functionally implicated in through information gained regarding the variant's involvement in molecular
770 phenotype experiments, chromatin interaction experiments, *in silico* function predictions and distance
771 between the variant and the gene's canonical transcription start site. The most likely candidate gene was
772 then used to investigate the placenta relevant cells that the gene is expressed in using information on the
773 Open Targets Platform and The Human Protein Atlas websites. The international Mouse Phenotyping
774 Consortium website was used to identify mouse models that found associations with placental pathology
775 after removal of the gene in single-gene knockout mice. Finally, further information was garnered through
776 searching publications for which the candidate gene was specifically implicated in placental biology.

778

779 Lookups of SNPs in GWAS of other phenotypes

780 We looked at associations between our independent PW-associated SNPs and other phenotypes within the
781 phenoscanner⁶². We looked for associations with the SNP itself, SNPs in LD ($r^2 = 1$, and $r^2 \geq 0.8$). We
782 additionally looked at associations between the independent PW SNPs in GWAS for nausea and vomiting of
783 pregnancy, hyperemesis gravidarum³³, preeclampsia³⁴, gestational duration³⁵, miscarriage (recurrent and
784 spontaneous)³⁶, and 10 cytokines assayed from neonatal blood spots³⁷ ([Supplementary Table 17](#)).

785

786 Mendelian randomization analysis

787 We then performed two-sample Mendelian randomization analyses with own and offspring PW as
788 outcomes. The exposures used included height, fasting glucose, disposition index of insulin secretion,
789 insulin sensitivity, systolic blood pressure (SBP) and diastolic blood pressure (DBP) using the same genetic
790 instruments as the previous GWAS of BW ([Supplementary Table 18](#))¹⁵. We estimated both the effect of
791 each maternal exposure on PW, and also the effect of the fetal genetic predisposition to each exposure on
792 PW. For the latter, we made the assumption that SNP-exposure effects in the fetus would be the same as in
793 the adult samples in which they were identified. Effect sizes were converted to g using the value of 1 SD of
794 PW of 132.5 g. We additionally used two-sample Mendelian randomization with its own PW as the
795 exposure, and gestational age, and preeclampsia as outcomes. The SNP-PW associations were taken from
796 our GWAS of PW, and the WLM-adjusted PW analysis. The SNP associations for all other traits were taken
797 from external sources ([Supplementary Table 17](#)). To estimate the independent fetal associations for
798 gestational age and preeclampsia, we first transformed the preeclampsia log odds ratios to the liability
799 scale⁶³, then applied the WLM in the same way as for PW. The preeclampsia independent fetal effects were
800 then transformed to log odds ratios for analysis. A population prevalence for preeclampsia of 4.6% was
801 used for the transformations⁶⁴. We applied the inverse-variance weighted Mendelian randomization
802 method, with MR-Egger⁶⁵, Weighted Median, and Penalised Weighted Median⁶⁶ acting as sensitivity
803 analysis to test for robustness to Mendelian randomization assumptions.

804

805 Polygenic scores

806 To investigate a possible association between PW and future risk of neuropsychiatric disease, we
807 conducted analyses in the Initiative for Integrative Psychiatric Research (iPSYCH) cohort. The iPSYCH cohort
808 is a Danish population based case-cohort sample including 141,215 individuals, out of which 50,615
809 constitute a population-representative sample and the remainder are individuals with one or more
810 neuropsychiatric disease diagnoses⁶⁷. After restriction to individuals of European ancestries born at
811 gestational ages between 37 and 42 weeks, 100,094 individuals remained for analysis, including 20,328
812 cases of ADHD, 28,672 cases of affective disorder, 17,362 cases of autism spectrum disorder, 4,052 cases of
813 schizophrenia, and population-based sample of 32,995 individuals without any one of the four disorders.
814 Placental weight data from the Danish Medical Birth Register were available for 33,035 of these individuals
815 (9,200 cases of ADHD, 2,946 cases of affective disorder, 9,678 cases of autism spectrum disorder, 239 cases
816 of schizophrenia, and 13,113 controls).

817 We redid the fetal meta-analysis for PW excluding the iPSYCH data, and based on the resulting summary
818 statistics and a genetic correlation matrix created from the iPSYCH genotypes, we used LD-pred2-auto⁶⁸ to
819 generate polygenic scores (PGS) for PW. Next, we regressed observed PW on ten fetal PW PGS quantiles,

820 including sex, gestational age and ten principal components as covariates in the model. The linear
821 regressions were done separately for the population controls and the four neuropsychiatric diseases. We
822 also used logistic regression to assess the association between either 1) observed PW, or 2) fetal PGS of
823 PW, and future risk of neuropsychiatric disease, including sex, gestational age and ten principal
824 components as covariates in the model. In these analyses, the observed PW and the fetal PGS were first
825 standardized to have mean 0 and variance 1.

826

827

828 **URLs**

829 <https://geneimprint.com/>

830 <https://platform.opentargets.org/>

831 <https://www.proteinatlas.org/>

832 <https://www.mousephenotype.org/>

833 <https://www.ldsc.broadinstitute.org/>

834 <https://www.ebi.ac.uk/gwas/home>

835

836

837 **Data availability**

838 Individual cohorts contributing to the meta-analysis should be contacted directly as each cohort has
839 different data access policies. GWAS summary statistics from this study are available via the EGG website
840 (<https://egg-consortium.org/>).

841

842

843 **Ethics**

844 Details of ethical approvals for the contributing studies are found in the Supplementary Information.

845

846

847 **Author contributions**

848 The central analysis and manuscript drafting team included R.N.B., C.F., M.Vaudel, X.W., L.S., G.-H.M.,
849 D.M.E., B.J., M.-R.J., G.Z., M.-F.H, S.J., R.M.F., B.F., P.R.N.

850

851 Sample collection, genotyping and/or phenotyping were performed and/or directed by C.F., M.Vaudel, G.-
852 H.M., Ø.H., P.S.-N., K.B., D.W., J.R.B., H.C., K.Hao, O.A.A., B.O.Å., M.A., L.Bhatta, L.Bouchard, B.M.B, S.B.,
853 J.B.-G., P.E., L.E., C.Erikstrup, M.E., S.F., R.G., F.G.E., J.G., D.M.H., E.K., C.S.M., E.A.N., M.N., C.N.A.P., O.B.P.,

854 F.R., B.M.S., C.S., I.S., L.W.T., H.U., M.Vaarasmaki, B.J.V., C.J.W., T.A.L., D.J.G.-B., M.B., T.H., E.R.P., R.R.,
855 S.R.O., C.E.P., V.W.V.J., J.F.F., A.T.H., M.M., D.A.L., K.Hveem, T.W., H.S.N., P.M., B.J., M.-R.J., M.-F.H., S.J.,
856 R.M.F., B.F., P.R.N.

857

858 Statistical analysis was performed by R.N.B., C.F., M.Vaudel, X.W., J.C., G.-H.M., L.S., C.Albiñana, J.R., J.F.,
859 S.E.S., K.T., C.A.W., S.Srinivasan, C.S.S., J.R.B., C.Allard, M.G., T.K., D.J.L., F.W., H.C., K.Hao, M.A., F.G.E., J.G.,
860 B.J.V., T.A.L., M.B., J.F.F., D.M.E., G.Z., B.F.

861

862 Data was interpreted by R.N.B., C.F., M.Vaudel, X.W., L.S., G.-H.M., J.C., Ø.H., P.S.-N., C.Albiñana, J.R., K.T.,
863 S.Srinivasan, C.Allard, M.G., F.W., P.-É.J., B.O.Å., L.Bhatta, B.M.B., C.Ebbing, P.E., S.F., J.G., E.K., C.N.A.P.,
864 F.R., S.Seibert, M.Vaarasmaki, C.J.W., E.R.P., R.R., V.W.V.J., J.F.F., D.A.L., K.Hveem, D.M.E., B.J., M.-R.J., G.Z.,
865 M.-F.H., S.J., R.M.F., B.F., P.R.N.

866

867 All authors contributed to the final version of the manuscript.

868

869

870 **Competing interests**

871 O.A.A. is a consultant to HealthLytix. B.J.V. is on Allelica's scientific advisory board. C.J.W.'s spouse works
872 for Regeneron Pharmaceuticals. D.A.L. has received support from Roche Diagnostics and Medtronic Ltd for
873 research unrelated to that presented here. H.S.N. has received speaker's fees from Ferring
874 Pharmaceuticals, Merck A/S, Astra Zeneca, Cook Medical, Ibsa Nordic.

875

876

877 **Acknowledgements**

878 We are grateful to Drs. Mirjana Efremova and Sarah A. Teichmann who shared the maternal-fetal interface
879 single cell RNA data. Full acknowledgements and details of supporting grants are found in the
880 Supplementary Information.

881

882

883 **References**

884 1. Burton, G. J. & Jauniaux, E. Pathophysiology of placental-derived fetal growth restriction. *Am. J.*

885 *Obstet. Gynecol.* **218**, S745–S761 (2018).

886 2. Vahanian, S. A., Lavery, J. A., Ananth, C. V. & Vintzileos, A. Placental implantation abnormalities and

887 risk of preterm delivery: a systematic review and metaanalysis. *American Journal of Obstetrics and*

888 *Gynecology* **213**, S78–S90 (2015).

- 889 3. Fisher, S. J. Why is placentation abnormal in preeclampsia? *Am. J. Obstet. Gynecol.* **213**, S115–22
890 (2015).
- 891 4. Magee, L. A., Nicolaides, K. H. & von Dadelszen, P. Preeclampsia. *N. Engl. J. Med.* **386**, 1817–1832
892 (2022).
- 893 5. Gaillard, R., Steegers, E. A. P., Tiemeier, H., Hofman, A. & Jaddoe, V. W. V. Placental vascular
894 dysfunction, fetal and childhood growth, and cardiovascular development: the generation R study.
895 *Circulation* **128**, 2202–2210 (2013).
- 896 6. Kratimenos, P. & Penn, A. A. Placental programming of neuropsychiatric disease. *Pediatr. Res.* **86**, 157–
897 164 (2019).
- 898 7. Burton, G. J., Fowden, A. L. & Thornburg, K. L. Placental Origins of Chronic Disease. *Physiol. Rev.* **96**,
899 1509–1565 (2016).
- 900 8. Nelson, D. M. How the placenta affects your life, from womb to tomb. *Am. J. Obstet. Gynecol.* **213**,
901 S12–3 (2015).
- 902 9. Ray, J. G., Vermeulen, M. J., Schull, M. J. & Redelmeier, D. A. Cardiovascular health after maternal
903 placental syndromes (CHAMPS): population-based retrospective cohort study. *Lancet* **366**, 1797–1803
904 (2005).
- 905 10. Risnes, K. R., Romundstad, P. R., Nilsen, T. I. L., Eskild, A. & Vatten, L. J. Placental weight relative to
906 birth weight and long-term cardiovascular mortality: findings from a cohort of 31,307 men and
907 women. *Am. J. Epidemiol.* **170**, 622–631 (2009).
- 908 11. Thornburg, K. L., O’Tierney, P. F. & Louey, S. Review: The placenta is a programming agent for
909 cardiovascular disease. *Placenta* **31 Suppl**, S54–9 (2010).
- 910 12. Haavaldsen, C., Samuelson, S. O. & Eskild, A. The association of maternal age with placental weight: a
911 population-based study of 536 954 pregnancies. *BJOG: An International Journal of Obstetrics &*
912 *Gynaecology* **118**, 1470–1476 (2011).
- 913 13. Matthiesen, N. B. *et al.* Congenital Heart Defects and Indices of Placental and Fetal Growth in a

- 914 Nationwide Study of 924 422 Liveborn Infants. *Circulation* **134**, 1546–1556 (2016).
- 915 14. Salafia, C. M. *et al.* Placental characteristics and birthweight. *Paediatr. Perinat. Epidemiol.* **22**, 229–239
916 (2008).
- 917 15. Warrington, N. M. *et al.* Maternal and fetal genetic effects on birth weight and their relevance to
918 cardio-metabolic risk factors. *Nat. Genet.* **51**, 804–814 (2019).
- 919 16. Juliusdottir, T. *et al.* Distinction between the effects of parental and fetal genomes on fetal growth.
920 *Nat. Genet.* **53**, 1135–1142 (2021).
- 921 17. Peng, S. *et al.* Genetic regulation of the placental transcriptome underlies birth weight and risk of
922 childhood obesity. *PLoS Genet.* **14**, e1007799 (2018).
- 923 18. Turco, M. Y. & Moffett, A. Development of the human placenta. *Development* **146**, (2019).
- 924 19. Vento-Tormo, R. *et al.* Single-cell reconstruction of the early maternal-fetal interface in humans.
925 *Nature* **563**, 347–353 (2018).
- 926 20. Grotzinger, A. D. *et al.* Genomic structural equation modelling provides insights into the multivariate
927 genetic architecture of complex traits. *Nat Hum Behav* **3**, 513–525 (2019).
- 928 21. Moen, G.-H. *et al.* Using Genomic Structural Equation Modeling to Partition the Genetic Covariance
929 Between Birthweight and Cardiometabolic Risk Factors into Maternal and Offspring Components in
930 the Norwegian HUNT Study. *Behav. Genet.* (2022) doi:10.1007/s10519-022-10116-9. Epub ahead of
931 print.
- 932 22. Magnus, P. *et al.* Cohort Profile Update: The Norwegian Mother and Child Cohort Study (MoBa). *Int. J.*
933 *Epidemiol.* **45**, 382–388 (2016).
- 934 23. Kong, A. *et al.* Parental origin of sequence variants associated with complex diseases. *Nature* **462**, 868–
935 874 (2009).
- 936 24. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in genome-
937 wide association studies. *Nature Genetics* **47**, 291–295 (2015).
- 938 25. Peng, S. *et al.* Expression quantitative trait loci (eQTLs) in human placentas suggest developmental

- 939 origins of complex diseases. *Hum. Mol. Genet.* **26**, 3432–3441 (2017).
- 940 26. Groleau, M. *et al.* Comparative epigenome-wide analysis highlights placenta-specific differentially
941 methylated regions. *Epigenomics* **13**, 357–368 (2021).
- 942 27. Guillemette, L. *et al.* Genetics of Glucose regulation in Gestation and Growth (Gen3G): a prospective
943 prebirth cohort of mother–child pairs in Sherbrooke, Canada. *BMJ Open* **6**, e010031 (2016).
- 944 28. Jennewein, M. F. *et al.* Fc Glycan-Mediated Regulation of Placental Antibody Transfer. *Cell* **178**, 202–
945 215.e14 (2019).
- 946 29. Uhlén, M. *et al.* Proteomics. Tissue-based map of the human proteome. *Science* **347**, 1260419 (2015).
- 947 30. Dickinson, M. E. *et al.* Corrigendum: High-throughput discovery of novel developmental phenotypes.
948 *Nature* **551**, 398 (2017).
- 949 31. Sun, B. B. *et al.* Genomic atlas of the human plasma proteome. *Nature* **558**, 73–79 (2018).
- 950 32. Seixas, S. & Marques, P. I. Known Mutations at the Cause of Alpha-1 Antitrypsin Deficiency an Updated
951 Overview of SERPINA1 Variation Spectrum. *Appl. Clin. Genet.* **14**, 173–194 (2021).
- 952 33. Fejzo, M. S. *et al.* Placenta and appetite genes GDF15 and IGFBP7 are associated with hyperemesis
953 gravidarum. *Nat. Commun.* **9**, 1178 (2018).
- 954 34. Steinthorsdottir, V. *et al.* Genetic predisposition to hypertension is associated with preeclampsia in
955 European and Central Asian women. *Nat. Commun.* **11**, 5976 (2020).
- 956 35. Zhang, G. *et al.* Genetic Associations with Gestational Duration and Spontaneous Preterm Birth. *N.*
957 *Engl. J. Med.* **377**, 1156–1167 (2017).
- 958 36. Laisk, T. *et al.* The genetic architecture of sporadic and multiple consecutive miscarriage. *Nat.*
959 *Commun.* **11**, 5980 (2020).
- 960 37. Wang, Y. *et al.* Genome-wide association study identifies 16 genomic regions associated with
961 circulating cytokines at birth. *PLoS Genet.* **16**, e1009163 (2020).
- 962 38. Chen, J. *et al.* Dissecting maternal and fetal genetic effects underlying the associations between
963 maternal phenotypes, birth outcomes, and adult phenotypes: A mendelian-randomization and

- 964 haplotype-based genetic score analysis in 10,734 mother-infant pairs. *PLoS Med.* **17**, e1003305 (2020).
- 965 39. Johnsen, S. L. *et al.* Fetal size in the second trimester is associated with the duration of pregnancy,
966 small fetuses having longer pregnancies. *BMC Pregnancy Childbirth* **8**, 25 (2008).
- 967 40. Shields, B. M. *et al.* Mutations in the glucokinase gene of the fetus result in reduced placental weight.
968 *Diabetes Care* **31**, 753–757 (2008).
- 969 41. Hattersley, A. T. *et al.* Mutations in the glucokinase gene of the fetus result in reduced birth weight.
970 *Nat. Genet.* **19**, 268–270 (1998).
- 971 42. Macdonald-Wallis, C., Tilling, K., Fraser, A., Nelson, S. M. & Lawlor, D. A. Associations of blood pressure
972 change in pregnancy with fetal growth and gestational age at delivery: findings from a prospective
973 cohort. *Hypertension* **64**, 36–44 (2014).
- 974 43. Tyrrell, J. *et al.* Genetic Evidence for Causal Relationships Between Maternal Obesity-Related Traits
975 and Birth Weight. *JAMA* **315**, 1129–1140 (2016).
- 976 44. Lee, M. P. *et al.* Loss of imprinting of a paternally expressed transcript, with antisense orientation to
977 KVLQT1, occurs frequently in Beckwith-Wiedemann syndrome and is independent of insulin-like
978 growth factor II imprinting. *Proc. Natl. Acad. Sci. U. S. A.* **96**, 5203–5208 (1999).
- 979 45. Brioude, F. *et al.* Expert consensus document: Clinical and molecular diagnosis, screening and
980 management of Beckwith-Wiedemann syndrome: an international consensus statement. *Nat. Rev.*
981 *Endocrinol.* **14**, 229–249 (2018).
- 982 46. Tan, G. S. Diabetes, Metabolic Abnormalities, and Glaucoma. *Archives of Ophthalmology* **127**, 1354
983 (2009).
- 984 47. Müssig, K. *et al.* Association of type 2 diabetes candidate polymorphisms in KCNQ1 with incretin and
985 insulin secretion. *Diabetes* **58**, 1715–1720 (2009).
- 986 48. Hivert, M.-F. *et al.* Interplay of Placental DNA Methylation and Maternal Insulin Sensitivity in
987 Pregnancy. *Diabetes* **69**, 484–492 (2020).
- 988 49. Gray, K. J., Saxena, R. & Karumanchi, S. A. Genetic predisposition to preeclampsia is conferred by fetal

- 989 DNA variants near FLT1, a gene involved in the regulation of angiogenesis. *Am. J. Obstet. Gynecol.* **218**,
990 211–218 (2018).
- 991 50. Burton, G. J., Redman, C. W., Roberts, J. M. & Moffett, A. Pre-eclampsia: pathophysiology and clinical
992 implications. *BMJ* **366**, l2381 (2019).
- 993 51. Dahlstrøm, B., Romundstad, P., Øian, P., Vatten, L. J. & Eskild, A. Placenta weight in pre-eclampsia.
994 *Acta Obstet. Gynecol. Scand.* **87**, 608–611 (2008).
- 995 52. Coorens, T. H. H. *et al.* Inherent mosaicism and extensive mutation of human placentas. *Nature* **592**,
996 80–85 (2021).
- 997 53. Rasmussen, M. *et al.* RNA profiles reveal signatures of future health and disease in pregnancy. *Nature*
998 **601**, 422–427 (2022).
- 999 54. Gong, S. *et al.* The RNA landscape of the human placenta in health and disease. *Nat. Commun.* **12**,
1000 2639 (2021).
- 1001 55. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association
1002 scans. *Bioinformatics* **26**, 2190–2191 (2010).
- 1003 56. Yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies
1004 additional variants influencing complex traits. *Nat. Genet.* **44**, 369–75, S1–3 (2012).
- 1005 57. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203–
1006 209 (2018).
- 1007 58. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits. *Nat. Genet.*
1008 **47**, 1236–1241 (2015).
- 1009 59. Giambartolomei, C. *et al.* Bayesian test for colocalisation between pairs of genetic association studies
1010 using summary statistics. *PLoS Genet.* **10**, e1004383 (2014).
- 1011 60. Bourgey, Dali, Eveleigh, Chen & Letourneau. GenPipes: an open-source framework for distributed and
1012 scalable genomic analyses. *Gigascience* **8**, 1–11 (2019).
- 1013 61. Taylor-Weiner, A. *et al.* Scaling computational genomics to millions of individuals with GPUs. *Genome*

- 1014 *Biol.* **20**, 228 (2019).
- 1015 62. Kamat, M. A. *et al.* PhenoScanner V2: an expanded tool for searching human genotype-phenotype
1016 associations. *Bioinformatics* **35**, 4851–4853 (2019).
- 1017 63. Gillett, A. C., Vassos, E. & Lewis, C. M. Transforming Summary Statistics from Logistic Regression to the
1018 Liability Scale: Application to Genetic and Environmental Risk Scores. *Hum. Hered.* **83**, 210–224 (2018).
- 1019 64. Abalos, E., Cuesta, C., Grosso, A. L., Chou, D. & Say, L. Global and regional estimates of preeclampsia
1020 and eclampsia: a systematic review. *Eur. J. Obstet. Gynecol. Reprod. Biol.* **170**, 1–7 (2013).
- 1021 65. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid instruments: effect
1022 estimation and bias detection through Egger regression. *Int. J. Epidemiol.* **44**, 512–525 (2015).
- 1023 66. Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent Estimation in Mendelian
1024 Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet. Epidemiol.*
1025 **40**, 304–314 (2016).
- 1026 67. Bybjerg-Grauholm, J. *et al.* The iPSYCH2015 Case-Cohort sample: updated directions for unravelling
1027 genetic and environmental architectures of severe mental disorders. Preprint at
1028 <https://www.medrxiv.org/content/10.1101/2020.11.30.20237768v1> (2020).
- 1029 68. Privé, F., Arbel, J. & Vilhjálmsón, B. J. LDpred2: better, faster, stronger. *Bioinformatics* **36**, 5424–5431
1030 (2020).